N/A N=235 Culture Media for Borrelia Burgdorferi Sensu Lato
Erythema Migrans
Primary: Detection of Borrelia Burgdorferi Sensu Lato by Microscopy in Dark Field (Positive vs. Negative) — 102; 59 culture-positive skin samples
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=71 Xenodiagnosis After Antibiotic Treatment for Lyme Disease
Lyme Disease
Primary: Detection of Borrelia Burgdorferi in Ticks After Xenodiagnosis Procedure — 1; 0; 418; 319 Ticks
Phase 3 N=121 Six Versus Two Weeks Treatment With Doxycycline in Lyme Neuroborreliosis
Neuroborreliosis, Borrelia Burgdorferi
Primary: Difference in Composite Clinical Score From Inclusion to Six Months After Ended Treatment — 6.4; 6.4 units on a scale
Phase 2 N=11 Disulfiram: A Test of Symptom Reduction Among Patients With Previously Treated Lyme Disease
Fatigue · Quality of Life
Primary: Fatigue Severity Scale (FSS) — 4; 2 Participants
Phase 4 N=544 Comparison of Doxycycline and Cefuroxime Axetil for Treatment of Erythema Migrans: Clinical and Microbiological Outcome
Erythema Migrans · Post-Lyme Disease Symptoms
Primary: Objective Lyme Disease Manifestations and Post-Lyme Disease Symptoms at 14 Days — 30; 27 participants
Phase 2 N=572 Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. Randomized, Controlled, Observer-blind Phase 2 Study.
Lyme Borreliosis
Primary: GMTs (Geometric Mean Titers) for IgG (Immunoglobulin G) Against Each OspA (Outer Surface Protein A) Serotype ST1 to ST6 — 74.3; 101.9; 115.8; 21.7 U/mL
N/A N=15 Feasibility of Teleyoga for Treatment of Lyme Disease
Lyme Disease
Primary: Change of Pain Score From Baseline — 5.7; 4.8; 2.9; 4.6 score on a scale
Phase 2 N=625 Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study Population
Lyme Borreliosis
Primary: Percentage of Participants With Solicited Local and Solicited Systemic Adverse Events (AEs) Within 7 Days After Vaccination 1 — 63.0; 59.3; 12.5; 60.4 Percentage of…
N/A N=3,570 A School-Based Intervention to Reduce Lyme Disease
Lyme Disease
Primary: The Incidence of Lyme Disease Among Children and Families Living in an Endemic Area Using an Educational Intervention — 1; 1 Number of cases incident Lyme disease
N/A N=159 Tick-borne Illness and Clothing Study
Tick Bites · Tick-borne Illness
Primary: Work Related Tick Bites — 265; 780 tick bites — p=0.004
N/A N=15 Effect of Auricular Vagal Nerve Electrical Stimulation on Post-Treatment Lyme Disease Syndrome
Post-Treatment Lyme Disease Syndrome
Primary: Horowitz Lyme-Multiple Systemic Infectious Disease Syndrome Questionnaire — 50.5; 44.8; 33.8; 25.6 score on a scale — p=0.07
Phase 4 N=119 TBE (Tick-borne Encephalitis) Vaccination in Allergic Patients
Vaccine Responsiveness in Allergy · Vaccine Responsiveness During Allergy De-sensitization Treatment
Primary: Humoral TBE Immunity — 317.90; 250.10; 282.20 titer
Phase 3 N=3,547 Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy Children
Lyme Disease
Primary: Percentage of Participants With at Least 1 Local Reaction of Any Grade for up to 7 Days Following Study Vaccination 1 — 80.8; 34.8; 80.6; 14.6 Percentage of participants
N/A N=306 Duration of Antibiotic Treatment of Erythema Migrans
Erythema Chronicum Migrans
Primary: Objective Sequelae and Post-treatment Subjective New or Increased Symptoms (NOIS)in Patients Treated for Erythema Migrans With Doxycycline for 10 or 15 Days. — 79; 85…
Phase 4 N=205 Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination Schedules
Tick Borne Encephalitis · Virus Diseases
Primary: Percentage of Subjects With Detectable TBE Antibody Titers Greater Than or Equal to (≥) 2 — 95.83; 100.0; 97.17 Percentage of subjects
Phase 4 N=179 Tick-Borne Encephalitis (TBE) Seropersistence After First Booster and Response to a Second Booster in Children, Adolescents and Young Adults (Follow-Up to Study 700401)
Encephalitis, Tick-Borne
Primary: Seropositivity Rate Measured by Neutralization Test (NT) at 21-35 Days After the First Tick-borne Encephalitis (TBE) Booster Vaccination in Study 700401 — 100.0…
Phase 2 N=34 Humoral and Cellular Immunity for TBE Vaccination in Allogeneic HSCT Recipients
Tick Borne Encephalitis
Primary: Outcome of the Neutralization Test (Number of Subjects With Antibody Response Measured by Neutralization Assay) — 6; 14 Participants — p=<0.001
N/A N=231 Lumbar Puncture and Syphilis Outcome
Syphilis
Primary: Appropriate Decline in Serum Rapid Plasma Reagin Test (RPR) Titer — 38; 30 Participants — p=0.29
Phase 2 N=246 Alternative Schedule Study For VLA15, a Vaccine Candidate Against Lyme Borreliosis
Lyme Borreliosis
Primary: GMTs for IgG Against Each OspA Serotype — 278.5; 274.7; 21.0; 545.2 Units per milliliter (U/mL)
Phase 4 N=155 The Qure Study: Q-fever Fatigue Syndrome - Response to Treatment
Q Fever · Fatigue Syndrome, Chronic · Coxiella Infection
Primary: Checklist Individual Strength (CIS) — 31.6; 40.8; 37.8 score on a scale
Phase 1 N=64 Lipopolysaccharide (LPS) Challenge in Depression
Major Depressive Disorder
Primary: Change in Snaith-Hamilton Pleasure Scale (SHAPS) — 38.4; 33.2; 27.2; 26.2 units on a scale
Phase 2 N=94 Treatment and Natural History Study of Lymphomatoid Granulomatosis
Lymphomatoid Granulomatosis · Granulomatosis, Lymphomatoid · Non-Hodgkins Lymphoma
Primary: Overall Response Rate (ORR) — 53.45; 51.85; 57.14; 50.00 percentage of participants